Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

56.57 +0.40 (+0.71%)
Official Closing Price Updated: 7:00 PM EST, Jan 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9,534,187
Open 56.34
Bid (Size) 56.50 (5)
Ask (Size) 56.70 (2)
Prev. Close 56.17
Today's Range 56.31 - 56.80
52wk Range 39.35 - 61.08
Shares Outstanding 2,222,113,553
Dividend Yield 4.24%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 High-Yield Dividend Stocks to Buy Now and Hold at Least a Decade
Via The Motley Fool
Deal Dispatch: Vera Bradley Is A Mixed Bag, Modell's Ex-CEO Explores Party City
Vera Bradley faces shareholder pressure for underperformance, while acquisitions and restructurings define this week's deal landscape. 
Via Benzinga

Performance

YTD
-0.39%
-0.39%
1 Month
-3.08%
-3.08%
3 Month
+4.84%
+4.84%
6 Month
+42.64%
+42.64%
1 Year
+8.70%
+8.70%

More News

Read More
Bristol Myers Squibb to Present at J.P. Morgan’s 43rd Annual Healthcare Conference
From Bristol Myers Squibb
Via Business Wire
Decoding Bristol-Myers Squibb's Options Activity: What's the Big Picture?
Via Benzinga
Peering Into Bristol-Myers Squibb's Recent Short Interest
Via Benzinga
2 High-Yield Dividend Stocks to Buy Early in 2025
Via The Motley Fool
Bristol Myers Squibb Stock Earns 83 RS Rating
Via Investor's Business Daily
U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo® (nivolumab) Indications1,2
From Bristol Myers Squibb
Via Business Wire
Exploring BRISTOL-MYERS SQUIBB CO's Technical Signals and Breakout Potential.
Via Chartmill
Schwab US Dividend Equity ETF Reverses In December: What's Going On?
Via Benzinga
Topics ETFs
Bristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib) in Adults with Psoriatic Arthritis
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer
From Bristol Myers Squibb
Via Business Wire
Got $500? This Top Dividend ETF Is a Great Buy After Its Recent Sell-Off.
Via The Motley Fool
Topics ETFs
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
Via Benzinga
Wall Street's Top 10 Stock Calls This Week - Saturday, Dec. 21
Via Talk Markets
Topics Stocks / Equities
Want Decades of Passive Income? 3 Stocks to Buy Right Now
Via The Motley Fool
Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services
Via Benzinga
3 High-Yielding Dividend Stocks That Retirees Can Rely On for Recurring Income
Via The Motley Fool
Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025
From Bristol Myers Squibb
Via Business Wire
Got $250? 2 Healthcare Stocks to Buy and Hold Forever
Via The Motley Fool
These 2 Stocks Just Declared Dividend Raises That Kick In Next Year. Should You Buy?
Via The Motley Fool
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers
Via FinancialNewsMedia
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers
From FN Media Group LLC
Via GlobeNewswire
Pfizer Sets Up For A Wild Ride In 2025 Amid Looming Threats From Starboard, Kennedy
Via Investor's Business Daily
Sanofi's 340B Credit Proposal Draws Federal Warning For Statutory Violation
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.